Hypereosinophilic Syndrome as a Rare Cause of Reversible Biventricular Heart Failure

Maria Bonou; Chris J Kapelios; George Benetos; Ioannis Moyssakis; Nefeli Giannakopoulou; Panagiotis Diamantopoulos; Penelope Korkolopoulou; Eleni Variami; John Barbetseas

doi:10.1016/j.cjca.2017.01.006

Hypereosinophilic Syndrome as a Rare Cause of Reversible Biventricular Heart Failure

Can J Cardiol. 2017 May;33(5):688.e5-688.e7. doi: 10.1016/j.cjca.2017.01.006. Epub 2017 Jan 20.

Authors

Maria Bonou¹, Chris J Kapelios², George Benetos², Ioannis Moyssakis², Nefeli Giannakopoulou³, Panagiotis Diamantopoulos³, Penelope Korkolopoulou⁴, Eleni Variami³, John Barbetseas²

Affiliations

¹ Department of Cardiology, Laikon General Hospital, Athens, Greece. Electronic address: [email protected].
² Department of Cardiology, Laikon General Hospital, Athens, Greece.
³ First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
⁴ Department of Pathology, National and Kapodistrian University of Athens, Athens, Greece.

PMID: 28347583
DOI: 10.1016/j.cjca.2017.01.006

Abstract

Hypereosinophilic syndrome is a rare entity that can develop secondary to overproduction of eosinophilopoietic cytokines or as idiopathic disease. Cardiac involvement, which occurs often, is divided into 3 stages, the latter of which is nonreversible and leads to severe heart failure. Early detection and treatment of the syndrome is essential. For this reason, genetic testing for the FIP1L1-PDGFRA fusion gene has recently been added to the diagnostic algorithm. Patients with this mutation are at increased risk for the development of cardiac involvement and typically respond to treatment with the tyrosine kinase inhibitor imatinib mesylate.

Publication types

Case Reports

MeSH terms

Adult
Anticoagulants / administration & dosage
Antineoplastic Agents / administration & dosage
Bone Marrow Examination / methods
Echocardiography / methods
Heart Failure* / diagnosis
Heart Failure* / etiology
Heart Failure* / physiopathology
Heart Failure* / therapy
Humans
Hypereosinophilic Syndrome* / complications
Hypereosinophilic Syndrome* / diagnosis
Hypereosinophilic Syndrome* / drug therapy
Hypereosinophilic Syndrome* / genetics
Imatinib Mesylate / administration & dosage*
Male
Mutation
Oncogene Proteins, Fusion / genetics
Prednisone / administration & dosage*
Receptor, Platelet-Derived Growth Factor alpha / genetics
Thrombosis* / diagnosis
Thrombosis* / drug therapy
Thrombosis* / etiology
Treatment Outcome
Warfarin / administration & dosage*
mRNA Cleavage and Polyadenylation Factors / genetics

Substances

Anticoagulants
Antineoplastic Agents
Oncogene Proteins, Fusion
mRNA Cleavage and Polyadenylation Factors
Warfarin
Imatinib Mesylate
FIP1L1-PDGFRA fusion protein, human
Receptor, Platelet-Derived Growth Factor alpha
Prednisone